EPISODE · Jul 2, 2024 · 4 MIN
FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic RET fusion-positive thyroid cancer
from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Listen to a soundcast of the May 29, 2024, FDA approval of Retevmo (selpercatinib) for patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Embed this episode
Ready to play
FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic RET fusion-positive thyroid cancer
No transcript for this episode yet
Similar Episodes
No similar episodes found.